ACCOUNT NO.
MED. REC. NO.
NAME
BIRTHDATE

Patient Identification

ALL ORDERS MUST BE MARKED IN INK WITH A CHECKMARK (✓) TO BE ACTIVE.

Weight: _____kg **Height:** _____cm

Allergies: _____

Diagnosis Code: _____

Treatment Start Date: _____ **Patient to follow up with provider on date:** _____

****This plan will expire after 365 days at which time a new order will need to be placed****

GUIDELINES FOR ORDERING

1. Send **FACE SHEET and H&P or most recent chart note**.
2. Ravulizumab-cwvz is part of FDA REMS Program
    a. Providers MUST be enrolled in the Ultomiris REMS program.
    b. Counsel patients using the Ultomiris patient safety card and patient safety brochure. Patients should carry the Ultomiris patient safety card at all times.
    c. Please see reference links below for enrollment forms and additional help
        i. https://ultomirisrems.com/
        ii. https://www.accessdata.fda.gov/drugsatfda_docs/rems/Ultomiris_2018_12_21_Prescriber_Enrollment_Form.pdf
        iii. https://www.accessdata.fda.gov/drugsatfda_docs/rems/Ultomiris_2018_12_21_Prescriber_Safety_Brochure.pdf
        iv. https://www.accessdata.fda.gov/drugsatfda_docs/rems/Ultomiris_2018_12_21_Patient_Safety_Brochure.pdf
        v. https://www.accessdata.fda.gov/drugsatfda_docs/rems/Ultomiris_2018_12_21_Patient_Safety_Card.pdf
3. Patients must receive the following meningococcal vaccine at least 2 weeks prior to treatment initiation:
    a. Meningococcal serogroups A, C, W, Y vaccine (MenACWY) -Menveo, Menactra, or MenQuadfi. These require booster shots every 5 years.
    Date of last vaccination: _____
    b. Meningococcal serogroup B vaccine -Bexsero or Trumenba. These require booster shots 1 year after primary series and every 2 to 3 years thereafter.
    Date of last vaccination: _____

    Documentation for vaccines must be sent with the order.
    Patients not vaccinated should be on prophylaxis antibiotics until vaccines are up to date. Patients who have been vaccinated less than 2 weeks prior to start of infusion should be on 2 weeks of antibacterial prophylaxis.
4. For patients switching from eculizumab to ravulizumab-cwvz, administer ravulizumab-cwvz loading dose 2 weeks after the last eculizumab infusion, and then administer maintenance doses once every 8 weeks, starting 2 weeks after loading dose administration.
5. Closely monitor patients for early signs and symptoms of meningococcal infections and evaluate immediately if infection is suspected. If ravulizumab-cwvz is administered to patients with active systemic infections, monitor for signs and symptoms of worsening infection.
6. Monitor patient after discontinuation for at least 16 weeks for signs and symptoms of hemolysis.
7. Consider penicillin prophylaxis for the duration of ravulizumab-cwvz therapy to potentially reduce the risk of meningococcal disease.

ACCOUNT NO.
MED. REC. NO.
NAME
BIRTHDATE

Patient Identification

ALL ORDERS MUST BE MARKED IN INK WITH A CHECKMARK (✓) TO BE ACTIVE.

PRE-SCREENING: (Results must be available prior to initiation of therapy):

- ☐ Meningococcal serogroups A, C, W, Y vaccine (MenACWY) -MenQuadfi, Menactra, or Menveo given on (dates) _____
- ☐ Meningococcal serogroup B vaccine -Bexsero or Trumenba given on (dates) _____

LABS:

- ☐ CBC with differential, Routine, ONCE, every visit
- ☐ LDH Total, routine, ONCE, every visit
- ☐ Labs already drawn. Date: _____

NURSING ORDERS:

1. VITAL SIGNS – Monitor and record vital signs, tolerance, and presence of infusion-related reactions prior to infusion and every 15 minutes throughout infusion.
2. Monitor for 1 hour after infusion is complete for signs and symptoms of infusion reaction. Monitoring may be discontinued by provider if no history of prior reaction.
3. Hold treatment and notify provider if patient is not up to date on meningococcal vaccination every 5 years for MenACWY (Menveo, Menactra, or MenQuadfi) or 1 year after primary series and every 2 to 3 years thereafter for MenB (either Bexsero or Trumenba).
4. Follow facility policies and/or protocols for vascular access maintenance with appropriate flush solution, declotting (alteplase), and/or dressing changes.

MEDICATION: Dose is based on weight at time of treatment (must check one)

Loading Dose:

ravulizumab-cwvz (ULTOMIRIS) in sodium chloride 0.9%, intravenous, ONCE, every visit

Patient weight 40-59.9 kg	☐ **2400 mg over 60 minutes**
Patient weight 60-99.9 kg	☐ **2700 mg over 45 minutes**
Patient weight 100 kg or greater	☐ **3000 mg over 30 minutes**

Maintenance Doses:

ravulizumab-cwvz (ULTOMIRIS) in sodium chloride 0.9%, intravenous, ONCE, every visit

Patient weight 40-59.9 kg	☐ **3000 mg over 60 minutes**
Patient weight 60-99.9 kg	☐ **3300 mg over 45 minutes**
Patient weight 100 kg or greater	☐ **3600 mg over 30 minutes**

Interval:

- ☐ Every 8 weeks beginning 2 weeks after loading dose
- ☐ Every 8 weeks beginning on date _____

ACCOUNT NO.
MED. REC. NO.
NAME
BIRTHDATE

Patient Identification

ALL ORDERS MUST BE MARKED IN INK WITH A CHECKMARK (✓) TO BE ACTIVE.

HYPERSENSITIVITY MEDICATIONS:

1. NURSING COMMUNICATION – If hypersensitivity or infusion reactions develop, temporarily hold the infusion and notify provider immediately. Administer emergency medications per the Treatment Algorithm for Acute Infusion Reaction (OHSU HC-PAT-133-GUD, HMC C-132). Refer to algorithm for symptom monitoring and continuously assess as grade of severity may progress.
2. diphenhydrAMINE (BENADRYL) injection, 25-50 mg, intravenous, AS NEEDED x 1 dose for hypersensitivity or infusion reaction
3. EPINEPHrine HCl (ADRENALIN) injection, 0.3 mg, intramuscular, AS NEEDED x 1 dose for hypersensitivity or infusion reaction
4. hydrocortisone sodium succinate (SOLU-CORTEF) injection, 100 mg, intravenous, AS NEEDED x 1 dose for hypersensitivity or infusion reaction
5. famotidine (PEPCID) injection, 20 mg, intravenous, AS NEEDED x 1 dose for hypersensitivity or infusion reaction

By signing below, I represent the following:
I am responsible for the care of the patient (*who is identified at the top of this form*);
I hold an active, unrestricted license to practice medicine in: ☐ Oregon ☐ _____ (*check box that corresponds with state where you provide care to patient and where you are currently licensed. Specify state if not Oregon*);

My physician license Number is # _____ (MUST BE COMPLETED TO BE A VALID PRESCRIPTION); and I am acting within my scope of practice and authorized by law to order Infusion of the medication described above for the patient identified on this form.

Provider signature: _____ **Date/Time:** _____

Printed Name: _____ **Phone:** _____ **Fax**: _____

ACCOUNT NO.
MED. REC. NO.
NAME
BIRTHDATE

Patient Identification

ALL ORDERS MUST BE MARKED IN INK WITH A CHECKMARK (✓) TO BE ACTIVE.

Central Intake:

Phone: 971-262-9645 (providers only) Fax: 503-346-8058

Please check the appropriate box for the patient's preferred clinic location:

☐ **Beaverton**
OHSU Knight Cancer Institute
15700 SW Greystone Court
Beaverton, OR 97006
Phone number: 971-262-9000
Fax number: 503-346-8058

☐ **NW Portland**
Legacy Good Samaritan campus
Medical Office Building 3, Suite 150
1130 NW 22nd Ave.
Portland, OR 97210
Phone number: 971-262-9600
Fax number: 503-346-8058

☐ **Gresham**
Legacy Mount Hood campus
Medical Office Building 3, Suite 140
24988 SE Stark
Gresham, OR 97030
Phone number: 971-262-9500
Fax number: 503-346-8058

☐ **Tualatin**
Legacy Meridian Park campus
Medical Office Building 2, Suite 140
19260 SW 65th Ave.
Tualatin, OR 97062
Phone number: 971-262-9700
Fax number: 503-346-8058

Infusion orders located at: www.ohsuknight.com/infusionorders